UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/642,946	08/18/2003	James W. Ryan	JR-14000-CON	4300
7590 03/09/2009 Cheryl H. Agris, Ph.D. P.O. Box 806 Pelham, NY 10803			EXAMINER	
			ZARA, JANE J	
remain, NT 10803			ART UNIT	PAPER NUMBER
			1635	
			MAIL DATE	DELIVERY MODE
			03/09/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Application/Control Number: 10/642,946 Page 2

Art Unit: 1635

Attachment

The amendments change the scope of the claims by replacing "comprising of" to "consisting of" language for the various fragments claimed. This will require new searches and new considerations for the claimed nucleotide fragments. The other introns, and their fragments have been withdrawn as non-elected inventions and will not be rejoined because the proper searches required for all of the introns claimed, and fragments of all of the introns claimed will indeed pose a serious burden on both the examiner and the PTO facilities in searching all of the patent and non-patent literature data bases. The inclusion of the language "encodes a polypeptide..." into the preamble of the methods claims will not render those claims free of the prior art of record because the prior art would still be found to perform all of the active steps recited in the claims. The finding that the coding region of the genomic nucleic acid encodes human adipocyte enhancer binding protein 1 activity does not preclude as art persons that have sequenced portions of the genomic sequences, regardless of whether they were previously identified as introns, exons, or coding regions.

For these reasons, the proposed amendments have not been entered.